Literature DB >> 15480842

Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).

C E Morrison1, J C Borod, M F Brin, T D Hälbig, C W Olanow.   

Abstract

Although improved cognition has been reported in patients with mild Parkinson's disease (PD) following the administration of levodopa, mixed results have been found in moderately-to-severely affected PD patients (MSPD), particularly in studies conducted since 1980. In the present study, 16 MSPD patients were tested on separate days, once following overnight levodopa withdrawal and once while optimally treated. A battery of neuropsychological tests that assess a range of cognitive functions (i.e., attention, language, visuospatial, memory, and executive), as well as a measure of depression, were used. Although patients performed better on a measure of confrontation naming in the untreated than in the treated condition, there were no significant differences for any of the other cognitive variables or for the depression scale variable. Thus, these data suggest that there are generally no adverse or beneficial effects of levodopa therapy on cognition in MSPD patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480842     DOI: 10.1007/s00702-004-0145-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  9 in total

1.  Attention and reach-to-grasp movements in Parkinson's disease.

Authors:  Cathy Lu; Aamir Bharmal; Zelma H Kiss; Oksana Suchowersky; Angela M Haffenden
Journal:  Exp Brain Res       Date:  2010-06-29       Impact factor: 1.972

Review 2.  Cognitive impairment and dementia in basal ganglia disorders.

Authors:  Julie C Stout; Shannon A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 3.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

4.  The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients.

Authors:  Livia Brusa; Valentina Pavino; Maria Carla Massimetti; Raffaele Bove; Cesare Iani; Paolo Stanzione
Journal:  Funct Neurol       Date:  2013 Jan-Mar

Review 5.  Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Authors:  Nandakumar S Narayanan; Robert L Rodnitzky; Ergun Y Uc
Journal:  Rev Neurosci       Date:  2013       Impact factor: 4.353

6.  Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson's disease.

Authors:  Arun Singh; Rachel C Cole; Arturo I Espinoza; Aron Evans; Scarlett Cao; James F Cavanagh; Nandakumar S Narayanan
Journal:  NPJ Parkinsons Dis       Date:  2021-02-15

7.  Parkinson's disease progression: implicit acquisition, cognitive and motor impairments, and medication effects.

Authors:  Rodrigo Pavão; André Frazão Helene; Gilberto Fernando Xavier
Journal:  Front Integr Neurosci       Date:  2012-08-10

Review 8.  Executive dysfunction in Parkinson's disease and timing deficits.

Authors:  Krystal L Parker; Dronacharya Lamichhane; Marcelo S Caetano; Nandakumar S Narayanan
Journal:  Front Integr Neurosci       Date:  2013-10-31

Review 9.  Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease.

Authors:  Krystal L Parker; Youngcho Kim; Stephanie L Alberico; Eric B Emmons; Nandakumar S Narayanan
Journal:  Dialogues Clin Neurosci       Date:  2016-03       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.